Marginal analyses revealed a statistically significant decline in DNM1 levels attributable to PCD among cancer patients (Δ ​= ​−20.6, 95 ​% CI ​= ​−36.8 to −4.3, P ​= ​0.013) but not among non-cancer controls (Δ ​= ​−3.2, 95 ​% CI ​= ​−14.3 to 8.0, P ​= ​0.576). The gene discussed is DNM1; the disease is cancer.